Aligos Therapeutics, Inc. Common Stock (ALGS)
Aligos Therapeutics, Inc. is a biotechnology company focused on developing therapies for liver diseases, viral infections, and related conditions. The company leverages novel approaches in drug discovery and development to address unmet medical needs, particularly targeting hepatitis B virus (HBV) and other chronic liver diseases.
Company News
Aligos Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted a non-qualified stock option to a newly hired employee as an inducement to join the company.
AstraZeneca's lung cancer drug Tagrisso has been approved by the European Commission for use in combination with chemotherapy as a first-line treatment for advanced EGFR-mutated non-small cell lung cancer. The approval was based on positive data from the FLAURA2 study, which showed Tagrisso plus chemotherapy reduced the risk of disease progressio...
Shares of Hello Group Inc. (NASDAQ: MOMO) jumped in pre-market trading after reporting results for the third quarter. The company said net revenues decreased by 5.9% year-over-year to RMB3,042.8 million ($417.1 million) during the third quarter. Non-GAAP diluted net income per ADS rose to RMB3.05 (US$0.42) from RMB2.60 in the year-ago period. He...
Analysts have put these on their list of penny stocks to buy. Do you agree? The post 4 Penny Stocks To Buy According To Analysts & Targets Over 600% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
The company is pulling the plug on a once-promising treatment targeting hepatitis B.